Geriatrik Üroonkolojide Radyoterapi

Extermann M, Brain E, Canin B, et al. Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. Lancet Oncology. 2021;22(1):e29-e36.

Horiot JC. Radiation therapy and the geriatric oncology patient. Journal of Clinical Oncology. 2007;25(14):1930-5.

VanderWalde N, Hurria A, Jagsi R. Improving Consistency and Quality of Care for Older Adults With Cancer: The Challenges of Developing Consensus Guidelines for Radiation Therapy. International Journal of Radiatherapy Oncology Biology Physics. 2017;98(4):721-5.

Sammon JD, Abdollah F, D'Amico A, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. European Urology. 2015;68(5):756-65.

Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998-2005.

Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Annuals of Oncology. 2012;23(8):2166-72.

Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. Journal of the American Geriatric Society. 2006;54(6):991-1001.

Dhakal P, Wichman CS, Pozehl B, et al. Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age? Future Oncology. 2022;18(3):311-21.

Aitken K, Mukherjee S. When Less is More: The Rising Tide of Hypofractionation. Clinical Oncology (R Coll Radiol). 2022;34(5):277-9.

Dawson LA, Jaffray DA. Advances in image-guided radiation therapy. Journal of Clinical Oncology. 2007;25(8):938-46.

Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA A Cancer Journal for Clinicians. 2025;75(1):10-45.

Quivy A, Daste A, Harbaoui A, et al. Optimal management of renal cell carcinoma in the elderly: a review. Clinical Interventians in Aging. 2013;8:433-42.

Pajunen H, Veitonmaki T, Huhtala H, et al. Prognostic factors of renal cell cancer in elderly patients: a population-based cohort study. Scientific Reports. 2024;14(1):6295.

Mathis S, Sierpina VS. Kidney Cancer Integrative Oncology: Possible Options for Care. Current Oncology Reports. 2023;25(9):1071-80.

Tran J, Ornstein MC. Clinical Review on the Management of Metastatic Renal Cell Carcinoma. JCO Oncology Practice. 2022;18(3):187-96.

Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. Journal of Urology. 2021;206(2):199-208.

Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annuals of Oncology. 2024;35(8):692-706.

NCCN Guidelines Version 3.2025 Kidney Cancer 2025 [updated 09.01.2025. 3.2025:[Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

Siva S, Bressel M, Sidhom M, et al. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncology. 2024;25(3):308-16.

Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018;124(5):934-42.

Hannan R, McLaughlin MF, Pop LM,et al. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer. European Urology. 2023;84(3):275-86.

Staehler M, Schuler T, Spek A, et al. Propensity Score-Matched Analysis of Single Fraction Robotic Radiosurgery Versus Open Partial Nephrectomy in Renal Cell Carcinoma: Oncological Outcomes. Cureus. 2022;14(1):e21623.

Siva S, Louie AV, Kotecha R, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncology. 2024;25(1):e18-e28.

Grubb WR, Ponsky L, Lo SS, et al. Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiotherapy and Oncology. 2021;155:138-43.

Kessler ER, Kukreja JB, Geiger CL, et al. Treating Elderly Patients With Muscle-Invasive Bladder Cancer. Journal of the National Comprehensive Cancer Network. 2020;18(6):783-90.

Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiology. 2013;37(3):219-25.

Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. Journal of Clinical Oncology. 2014;32(34):3801-9.

Fahmy O, Khairul-Asri MG, Schubert T, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urologic Oncology. 2018;36(2):43-53.

EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer 2025 [2025:[Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-Bladder-Cancer-2025.pdf.

NCCN Guidelines Version 1.2025 Bladder Cancer 2025 [Version 1.2025:[Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.

Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorganic Chemistery. 2019;88:102925.

Hoskin PJ, Rojas AM, Bentzen SM, et al. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. Journal of Clinical Oncology. 2010;28(33):4912-8.

Coen JJ, Zhang P, Saylor PJ, et al. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. Journal of Clinical Oncology. 2019;37(1):44-51.

Hurmuz P, Ozyigit G, Kilickap S, et al. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes? Urologic Oncology. 2021;39(6):368 e19- e29.

Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. Journal of Urology. 2011;185(1):72-8.

Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. European Urology. 2013;63(5):823-9.

Mohamed HAH, Salem MA, Elnaggar MS, et al. Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine. Cancer Radiotherapie. 2018;22(3):236-40.

Westergren DO, Gardmark T, Lindhagen L, et al. A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014. Journal of Urology. 2019;202(5):905-12.

Choudhury A, Porta N, Hall E, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncology. 2021;22(2):246-55.

Huddart R, Hafeez S, Lewis R, et al. Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. International Journal of Radiatherapy Oncology Biology Physics. 2021;110(2):412-24.

Birsen Yücel EE. Definitive radiotherapy or chemoradiotherapy results and side effects in elderly bladder cancer patients. Cumhuriyet Medical Journal. 2019;41(4):703-11.

Ali A, Song YP, Mehta S, et al. Palliative Radiation Therapy in Bladder Cancer-Importance of Patient Selection: A Retrospective Multicenter Study. International Journal of Radiatherapy Oncology Biology Physics. 2019;105(2):389-93.

Duchesne GM, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. International Journal of Radiatherapy Oncology Biology Physics. 2000;47(2):379-88.

Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. Journal of Clinical Oncology. 2011;29(2):235-41.

Pettersson A, Robinson D, Garmo H, et al. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Annuals of Oncology. 2018;29(2):377-85.

Shaheen H, Salans MA, Mohamad O, et al. Age 70 +/- 5 Years and Cancer-Specific Outcomes After Treatment of Localized Prostate Cancer: A Systematic Review. International Journal of Radiatherapy Oncology Biology Physics. 2024;118(3):672-81.

Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. Journal of Urology. 2022;208(1):10-8.

NCCN Guidelines Version 2.2025 Prostate Cancer 2025 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299(3):289-95.

Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. New England Journal of Medicine. 2011;365(2):107-18.

Rider JR, Sandin F, Andren O, et al. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. European Urology. 2013;63(1):88-96.

Ogawa K, Nakamura K, Onishi H, et al. Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer. Anticancer Research. 2006;26(2B):1319-25.

Bekelman JE, Mitra N, Efstathiou J, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. International Journal of Radiatherapy Oncology Biology Physics. 2011;81(4):e325-34.

Yu T, Zhang Q, Zheng T, et al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures. PLoS One. 2016;11(5):e0154499.

Benitez CM, Chuong MD, Kunzel LA, et al. MRI-Guided Adaptive Radiation Therapy. Seminars in Radiation Oncology. 2024;34(1):84-91.

Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology. 2016;17(8):1047-60.

Tree AC, Ostler P, van der Voet H, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncology. 2022;23(10):1308-20.

Dasu A, Toma-Dasu I. Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients. Acta Oncology. 2012;51(8):963-74.

Catton CN, Lukka H, Gu CS, et al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology. 2017;35(17):1884-90.

Niazi T, Nabid A, Malagon T, et al. Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Genito-Urinaire de Quebec Led Phase 3 Trial. International Journal of Radiatherapy Oncology Biology Physics. 2024;118(1):52-62.

Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385-95.

van As N, Griffin C, Tree A, et al. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. New England Journal of Medicine. 2024;391(15):1413-25.

Rasmusson E, Gunnlaugsson A, Wieslander E, et al. Erectile Dysfunction and Absorbed Dose to Penile Base Structures in a Randomized Trial Comparing Ultrahypofractionated and Conventionally Fractionated Radiation Therapy for Prostate Cancer. International Journal of Radiatherapy Oncology Biology Physics. 2020;107(1):143-51.

Krauss DJ, Karrison T, Martinez AA, et al. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. Journal of Clinical Oncology. 2023;41(17):3203-16.

Kishan AU, Sun Y, Hartman H, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology. 2022;23(2):304-16.